Related Experiment Video
Updated: Jun 8, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
TNF superfamily: a growing saga of kidney injury modulators
Maria D Sanchez-Niño1, Alberto Benito-Martin, Sara Gonçalves
1IIS- Fundación Jiménez Díaz, 28040 Madrid, Spain.
Abstract:
Members of the TNF superfamily participate in kidney disease. Tumor necrosis factor (TNF) and Fas ligand regulate renal cell survival and inflammation, and therapeutic targeting improves the outcome of experimental renal injury. TNF-related apoptosis-inducing ligand (TRAIL and its potential decoy receptor osteoprotegerin are the two most upregulated death-related genes in human diabetic nephropathy. TRAIL activates NF-kappaB in tubular cells and promotes apoptosis in tubular cells and podocytes, especially in a high-glucose environment. By contrast, osteoprotegerin plays a protective role against TRAIL-induced apoptosis. Another family member, TNF-like weak inducer of apoptosis (TWEAK induces inflammation and tubular cell death or proliferation, depending on the microenvironment. While TNF only activates canonical NF-kappaB signaling, TWEAK promotes both canonical and noncanonical NF-kappaB activation in tubular cells, regulating different inflammatory responses. TWEAK promotes the secretion of MCP-1 and RANTES through NF-kappaB RelA-containing complexes and upregulates CCl21 and CCL19 expression through NF-kappaB inducing kinase (NIK-) dependent RelB/NF-kappaB2 complexes. In vivo TWEAK promotes postnephrectomy compensatory renal cell proliferation in a noninflammatory milieu. However, in the inflammatory milieu of acute kidney injury, TWEAK promotes tubular cell death and inflammation. Therapeutic targeting of TNF superfamily cytokines, including multipronged approaches targeting several cytokines should be further explored.
Insights
Tumor necrosis factor (TNF) superfamily members are involved in kidney disease. Targeting these cytokines, like TNF-related apoptosis-inducing ligand (TRAIL) and TNF-like weak inducer of apoptosis (TWEAK), may offer new therapeutic strategies for kidney injury.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Members of the Tumor Necrosis Factor (TNF) superfamily play significant roles in kidney disease pathogenesis.
- TNF and Fas ligand influence renal cell survival and inflammation, with therapeutic targeting showing promise in experimental models.
- Increased expression of TNF-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin is observed in human diabetic nephropathy.
Purpose of the Study:
- To elucidate the specific roles of TNF superfamily members, including TRAIL and TNF-like weak inducer of apoptosis (TWEAK), in kidney disease.
- To investigate the signaling pathways activated by these cytokines in renal cells.
- To evaluate the potential of targeting TNF superfamily cytokines for therapeutic intervention in kidney injury.
Main Methods:
- Analysis of gene expression in human diabetic nephropathy.
- In vitro studies on tubular cells and podocytes, including high-glucose environments.
- Investigation of NF-kappaB signaling pathways (canonical and noncanonical) activated by TNF and TWEAK.
- In vivo studies examining TWEAK's role in postnephrectomy compensatory proliferation and acute kidney injury.
Main Results:
- TRAIL promotes apoptosis in tubular cells and podocytes, particularly under high-glucose conditions, while osteoprotegerin confers protection.
- TWEAK induces inflammation and cell death or proliferation depending on the microenvironment.
- TWEAK differentially activates NF-kappaB pathways, influencing the expression of chemokines (MCP-1, RANTES, CCL21, CCL19) and regulating renal cell proliferation or death in different injury contexts.
Conclusions:
- TNF superfamily members are key regulators of renal cell fate and inflammation in kidney disease.
- TRAIL and TWEAK exhibit distinct and context-dependent effects on renal cells, impacting apoptosis, proliferation, and inflammation.
- Targeting multiple TNF superfamily cytokines presents a promising therapeutic avenue for managing kidney diseases.
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome I : Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care

